A common promoter variant of the gene encoding cyclooxygenase-1 (PTGS1) is related to decreased incidence ofmyocardial infarction in patients with coronary artery disease
Date
2011
Authors
Latkovskis, Gustavs
Licis, Normunds
Krivmane, Baiba
Erglis, Andrejs
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Cyclooxigenase (COX)-1, formally known as prostanglandin endoperoxideH
synthetase-1,mediates synthesis of prostaglandin H2,which
is subsequently converted to various biologically active metabolites
including thromboxane (TX) A2 [1]. TXA2 is synthesized and released by
activated platelets and strongly reinforces thrombus formation, a critical
pathway in the pathogenesis of myocardial infarction (MI). Inhibition of
COX-1-derived TXA2 in platelets by low-dose aspirin administration
reduces incidence of MI [2]. Hypothetically, MI-risk could also be
modified by genetic variants that affect activity or expression of COX-1.
Many single nucleotide polymorphisms (SNP) in the gene encoding
COX-1 (PTGS1) have been described; including functional alterations in
both coding and non-coding regions [3,4].We have evaluated if two of
such variations are related to the risk ofMI in a historic cohort of patients
with coronary artery disease (CAD).
Description
Keywords
Research Subject Categories::MEDICINE